It's not a miracle cure, it's just a nicely different way of attacking a problem. It still has tradeoffs - I'm not versed on what they all are, but its tradeoffs are of a different kind than of small molecules. A few guesses of what those tradeoffs might look like: A peptide will be more expensive to synthesize in bulk, it will not have as long of a shelf-life, it likely has a different (not perfect) resistance mechanism and will be more or less effective on different specific microbes. It's likely not as effective on a per/molecule basis. And it's much larger, meaning it will have a greater difficulty diffusing through the body of an organism - and might actually be degraded more quickly once inside an organism because it's peptide-like.
But the mere fact that there are alternative tools in our toolbox for different scenarios is useful in our fight against disease (if not a 'miracle').
DRGN1 is not the first of such antimicrobial peptides, but it was found in a systematic way, and once it was found it was systematically made more effective. This hints at workflows to mine and refine more genetically encoded peptides like it in the future.
But the mere fact that there are alternative tools in our toolbox for different scenarios is useful in our fight against disease (if not a 'miracle').
DRGN1 is not the first of such antimicrobial peptides, but it was found in a systematic way, and once it was found it was systematically made more effective. This hints at workflows to mine and refine more genetically encoded peptides like it in the future.